SLSP 03
Alternative Names: SLSP-03Latest Information Update: 25 Jan 2021
Price :
$50 *
At a glance
- Originator Salspera
- Class Antineoplastics; Bacteria; Gene therapies; Immunotherapies; Single-domain antibodies
- Mechanism of Action Bacteria replacements; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Preclinical Solid tumours